Get the Stockscreener App
11.85
0.68%
0.08
Neogenomics Inc stock is traded at $11.85, with a volume of 1.13M.
It is up +0.68% in the last 24 hours and up +18.50% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$11.77
Open:
$11.85
24h Volume:
1.13M
Relative Volume:
0.36
Market Cap:
$1.53B
Revenue:
$628.25M
Net Income/Loss:
$-78.55M
P/E Ratio:
-19.11
EPS:
-0.62
Net Cash Flow:
$-29.73M
1W Performance:
-0.42%
1M Performance:
+18.50%
6M Performance:
+60.35%
1Y Performance:
-33.80%
1-Day Range:
$11.73
$11.96
1-Week Range:
$11.59
$12.20
52-Week Range:
$4.72
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
11.85 | 1.52B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
572.28 | 217.50B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.33 | 164.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.20 | 56.49B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
139.68 | 40.44B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.26 | 38.48B | 15.90B | 1.28B | 2.21B | 7.2842 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Value Recap: Will NeoGenomics Inc NG9 stock outperform foreign stocksJuly 2025 Retail & AI Enhanced Execution Alerts - moha.gov.vn
US Market Wrap: Why NeoGenomics Inc stock is trending among retail tradersJuly 2025 Summary & Safe Entry Point Identification - moha.gov.vn
Bellevue Group AG Reduces Stake in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics Inc Stock Analysis and ForecastTake Profit Strategies & Start Your Free Trading Journey Today - earlytimes.in
What analysts say about The Hershey Company stockShort Interest Overview & Free Long-Term Investment Planning - earlytimes.in
The Supreme Industries Limited (SUPREMEIND) Announces Strategic ShiftValue Traps to Avoid & Get Ahead with Our Profit-Packed Picks - earlytimes.in
Will New RaDaR MRD Data and Myeloid Profiling Advances Change NeoGenomics' (NEO) Diagnostics Narrative? - simplywall.st
NeoGenomics to Present New ctDNA Research at SABCS 2025 - BioSpace
NeoGenomics (NEO): Assessing Valuation After a 44% Three-Month Share Price Rebound - Yahoo Finance
Quantbot Technologies LP Buys New Holdings in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025 - BioSpace
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies a - pharmiweb.com
Risk Hedge: Can NeoGenomics Inc NG9 stock sustain margin levelsJuly 2025 Fed Impact & Verified Short-Term Plans - moha.gov.vn
Testing & Diagnostics Services Stocks Q3 Recap: Benchmarking NeoGenomics (NASDAQ:NEO) - The Globe and Mail
Personalized ctDNA detection and genomic profiling in the NeoRHEA Study - Nature
Is NeoGenomics Inc. (NG9) stock attractive for growth fundsWeekly Volume Report & Accurate Entry and Exit Point Alerts - Newser
How NeoGenomics Inc. stock benefits from tech adoptionJuly 2025 Update & AI Optimized Trading Strategy Guides - Newser
Will NeoGenomics Inc. (NG9) stock announce a stock splitGlobal Markets & Free High Return Stock Watch Alerts - Newser
Greenhouse Funds LLLP Boosts Stock Holdings in NeoGenomics, Inc. $NEO - MarketBeat
Can NeoGenomics Inc. (NG9) stock deliver double digit returnsNew Guidance & Expert Approved Momentum Trade Ideas - Newser
NeoGenomics, Inc. $NEO Shares Bought by Samjo Management LLC - MarketBeat
Will NeoGenomics Inc. (NG9) stock announce special dividendOil Prices & Technical Confirmation Trade Alerts - Newser
Is NeoGenomics Inc. (NG9) stock supported by free cash flowWeekly Trend Report & Risk Adjusted Swing Trade Ideas - Newser
Can NeoGenomics Inc. (NG9) stock survive global slowdownMarket Risk Summary & Daily Entry Point Trade Alerts - Newser
Geode Capital Management LLC Buys 26,224 Shares of NeoGenomics, Inc. $NEO - MarketBeat
American Century Companies Inc. Has $25.71 Million Stock Position in NeoGenomics, Inc. $NEO - MarketBeat
Ideas Watch: How rising interest rates impact NeoGenomics Inc. stockJuly 2025 Gainers & Reliable Volume Spike Alerts - BỘ NỘI VỤ
Insider Selling: NeoGenomics (NASDAQ:NEO) EVP Sells 20,916 Shares of Stock - MarketBeat
Neogenomics EVP Olivo sells $250k in NEO stock By Investing.com - Investing.com Canada
Neogenomics EVP Olivo sells $250k in NEO stock - Investing.com India
NEOGENOMICS EVP Alicia C Olivo Sells Shares - TradingView
Is NeoGenomics Inc a good long term investmentMarket Breadth Indicators & Access Insider-Level Stock Analysis - earlytimes.in
What analysts say about NeoGenomics Inc stockDividend Aristocrats List & Free Professional Investment Consultations - earlytimes.in
NeoGenomics, Inc. (NEO) Stock Forecasts - Yahoo Finance
NeoGenomics Reports Strong Revenue Growth Amid Rising Losses - MSN
NeoGenomics Inc (NG9.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
NeoGenomics, Fortrea, and Acadia Healthcare Shares Skyrocket, What You Need To Know - TradingView
First Week of January 2026 Options Trading For NeoGenomics (NEO) - Nasdaq
How NeoGenomics Inc. stock compares to market leadersWeekly Trade Review & Weekly Top Gainers Trade List - newser.com
Can NeoGenomics Inc. (NG9) stock sustain revenue momentumJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
How hedge fund analytics apply to NeoGenomics Inc. stock2025 Year in Review & Free High Accuracy Swing Entry Alerts - newser.com
Is NeoGenomics Inc. stock a buy on dipsLayoff News & Smart Swing Trading Techniques - newser.com
Connor Clark & Lunn Investment Management Ltd. Takes Position in NeoGenomics, Inc. $NEO - MarketBeat
Is NeoGenomics Inc. (NG9) stock cheap by valuation metricsDividend Hike & Proven Capital Preservation Tips - newser.com
Earnings visualization tools for NeoGenomics Inc.2025 Earnings Impact & High Conviction Trade Alerts - newser.com
Will NeoGenomics Inc. (NG9) stock beat value stocksJuly 2025 Snapshot & Smart Allocation Stock Tips - newser.com
Will earnings trigger a reversal in NeoGenomics Inc.Buy Signal & Safe Capital Growth Plans - newser.com
Will NeoGenomics Inc. (NG9) stock beat Nasdaq index returns2025 Historical Comparison & Precise Swing Trade Entry Alerts - newser.com
NeoGenomics at Stephens Conference: Strategic Growth Amid Pharma Challenges By Investing.com - Investing.com Canada
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.15%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):